emd 53998 has been researched along with cilostamide in 1 studies
| Studies (emd 53998) | Trials (emd 53998) | Recent Studies (post-2010) (emd 53998) | Studies (cilostamide) | Trials (cilostamide) | Recent Studies (post-2010) (cilostamide) |
|---|---|---|---|---|---|
| 112 | 0 | 9 | 192 | 0 | 67 |
| Protein | Taxonomy | emd 53998 (IC50) | cilostamide (IC50) |
|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.005 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.005 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 3.5775 | |
| Platelet-activating factor receptor | Homo sapiens (human) | 3.687 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 0.005 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 0.0502 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 0.0362 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
1 other study(ies) available for emd 53998 and cilostamide
| Article | Year |
|---|---|
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |